Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Merck

This Dividend Stock Is Beating the Market in 2026 and Yields 2.36%

Merck is beating the market year-to-date after a jump on positive Phase 3 data, while paying an annualized dividend of about $3.40 for a yield above 2.3%.

Barchart

Blue-Chip Stocks Are Looking Anything But Boring With Dividends and Big 2026 Gains

Coca-Cola, Chevron, and Merck have outperformed the S&P 500 in 2026, each pairing strong share-price gains with growing dividends backed by solid fundamentals.

MarketBeat

He Was Certain His Nose Smelled Like a Dead Mouse and Three Years of Testing Found Nothing

For three years, a man believed his nose gave off a dead mouse odor. Every exam came back clean, and the diagnosis turned out to be psychiatric.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

The First Cholesterol Pill in the PCSK9 Class Reaches Pharmacy Shelves at 315 Dollars a Month

The first oral PCSK9 inhibitor has reached US pharmacies at a $315 monthly list price. Here is what patients should ask before switching.

Medical Daily

Is Merck Stock Outperforming the Nasdaq?

Merck has surged past the broader Nasdaq Composite over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.

Barchart

US lawmakers question Health Secretary Kennedy on vaccine settlement disclosures

US senators are questioning Health Secretary Robert F. Kennedy Jr.'s explanation regarding his financial stake. His recent statements conflict with earlier testimony and ethics filings about Gardasil vaccine litigation. Kennedy previously stated he would transfer his interest in potential Gardasil fees to his son. However, he now claims neither he…

The Economic Times

Wolfe Research Just Upgraded Moderna Stock. Here's Why.

Moderna stock rallies as Wolfe Research upgrades it to "Peer Perform." But is there any further upside left in MRNA shares? Let’s find out!

Barchart

Read news from The Economist, FT, and more,
with one subscription

Moderna Added 45 Billion Dollars in a Day on a Melanoma Vaccine Result with No Effect Size Disclosed

Moderna and Merck's melanoma vaccine met its Phase 3 goals, but no effect size was released, and some analysts called the market reaction excessive.

Medical Daily

Trump called the MMR shot potentially lethal on camera. Then his own Medicare chief had to walk it back: ‘Not a lethal vaccine’

The government has overhauled its vaccine recommendations

We Got This Covered

BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing

BioNTech shares moved higher as the broader biotech sector reached a post-pandemic peak, lifted by positive late-stage cancer vaccine data from peers rather than new clinical results of its own.

Barchart

2 Biotech Stocks Shaping Up for Major Breakouts

Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.

MarketBeat

Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.

Moderna's cancer treatment could treat more than just Melanoma, though the stock's momentum is already stalling. Should you still buy the dip?

Barchart

NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough

NVAX stock surges amid biotech stock rally following Moderna and Merck cancer breakthrough.

Barchart

Patients and Researchers Push Back on Cancer Drug Doses That May Be Higher Than Treatment Requires

A KFF Health News investigation finds cancer drugs are often approved at doses higher than needed, leaving patients with avoidable side effects.

Medical Daily

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Moderna’s 177% Surge Has Investors Asking What Comes Next

Moderna shares surged 177% after its melanoma vaccine, developed with Merck, outperformed an established therapy in a late-stage trial, triggering a massive short squeeze.

International Business Times

Moderna, Merck's Cancer Vaccine Breakthrough Raises Hope For New Wave Of Personalized Treatments

Moderna and Merck's experimental cancer vaccine has delivered positive results in a late-stage melanoma trial, giving a major boost to personalized mRNA treatments as rivals including BioNTech and Roche pursue similar approaches.

International Business Times UK

Moderna's Vaccine Breakthrough Supported by AI: Musk Praises mRNA Despite 'Obvious Misuse During COVID'

Moderna and Merck's personalised mRNA vaccine shows promising Phase 3 results in melanoma treatment, potentially revolutionising cancer care with tailored immunotherapy.

Reason

$40 Trillion and Parents' Night Out

Plus: ICE chillin', Moderna-Merck melanoma advances, and more...

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Stocks Slip Before the Open as Bond Rout Resumes; Walmart Sinks After Earnings

September S&P 500 E-Mini futures (ESU26) are down -0.37%, and September Nasdaq 100 E-Mini futures (NQU26) are down -0.48% this morning, pointing to a lower open on Wall Street as Treasury yields resumed their climb.

The Independent UK

How does Moderna’s new melanoma vaccine work – and could it treat other cancers?

Melanoma is the most aggressive form of skin cancer causing about 2,600 deaths a year in the UK

Medical Daily

A Custom mRNA Therapy Built from Each Patient's Tumor Improved Melanoma Recurrence-Free Survival in a Phase 3 Trial

Merck and Moderna say intismeran autogene plus Keytruda met its primary endpoint in a Phase 3 melanoma trial. What the topline result does and does not show.

The Economic Times

Global Market: China, Hong Kong stocks rebound as healthcare and tech shares rally

China and Hong Kong stocks rebounded on Thursday, led by healthcare and technology shares, after a sharp selloff in the previous session. Fresh share buyback announcements also supported sentiment, while gains in South Korea and Japan helped broader Asian markets recover. Investors remained cautious amid heightened volatility.

International Business Times UK

Short Sellers Just Lost $5B on the Wrong Pharma Bet: Cancer Vaccine Sends Stock Soaring 177%

Moderna's shares surged 177% after positive cancer vaccine trial results, causing $5 billion losses for short sellers. This marks a potential shift beyond its COVID-19 vaccine business.

International Business Times UK

Moderna's Personalised Cancer Vaccine Clears Phase 3: How Soon Could Patients Receive It?

Moderna and Merck's personalised cancer vaccine shows positive Phase 3 results, reducing melanoma recurrence risk. Regulatory approval is pending, with potential market availability by 2027.

The Economic Times

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Merck and Moderna's personalized cancer vaccine shows promise for melanoma patients. This new treatment trains the immune system to target specific tumor mutations. The vaccine, combined with Keytruda, significantly reduced cancer recurrence in trials. Doctors are hopeful this approach will expand to treat many other cancer types. Further trials are…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.